Balyasny Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Balyasny Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$843K	Sell	13,900 -83,600	-86%	-$4.87M	﹤0.01%	2152
2025 Q4	$5.26M	Buy	97,500 +4,300	+5%	+$207K	0.01%	1365
2025 Q3	$4.2M	Buy	93,200 +66,700	+252%	+$3.12M	0.01%	1441
2025 Q2	$1.23M	Sell	26,500 -38,400	-59%	-$1.88M	﹤0.01%	1966
2025 Q1	$3.96M	Sell	64,900 -55,900	-46%	-$3.26M	0.01%	1361
2024 Q4	$6.83M	Buy	120,800 +14,500	+14%	+$810K	0.01%	1127
2024 Q3	$5.5M	Buy	+106,300	New	+$4.99M	0.01%	1215
2024 Q1	–	Sell	-9,900	Closed	-$508K	–	2631
2023 Q4	$508K	Sell	9,900 -513,400	-98%	-$26.9M	﹤0.01%	1949
2023 Q3	$30.4M	Buy	+523,300	New	+$32.1M	0.06%	425
2023 Q1	–	Sell	-248,400	Closed	-$17.9M	–	2670
2022 Q4	$17.9M	Hold	248,400	–	–	0.05%	529
2022 Q3	$17.7M	Buy	248,400 +212,700	+596%	+$15.4M	0.05%	468
2022 Q2	$2.75M	Buy	+35,700	New	+$2.72M	0.01%	1239
2022 Q1	–	Sell	-10,000	Closed	-$624K	–	2484
2021 Q4	$624K	Buy	+10,000	New	+$587K	﹤0.01%	1569
2021 Q3	–	Sell	-11,400	Closed	-$762K	–	1958
2021 Q2	$762K	Sell	11,400 -38,600	-77%	-$2.52M	﹤0.01%	1408
2021 Q1	$3.16M	Buy	+50,000	New	+$3.11M	0.02%	867
2019 Q4	–	Sell	-100,000	Closed	-$5.07M	–	1170
2019 Q3	$5.07M	Buy	+100,000	New	+$4.7M	0.03%	544
2019 Q2	–	Sell	-975,000	Closed	-$46.5M	–	1478
2019 Q1	$46.5M	Buy	975,000 +840,000	+622%	+$41.8M	0.31%	71
2018 Q4	$7.02M	Sell	135,000 -480,000	-78%	-$25.8M	0.05%	435
2018 Q3	$37.4M	Sell	615,000 -538,000	-47%	-$31.9M	0.17%	162
2018 Q2	$63.8M	Sell	1,153,000 -1,379,500	-54%	-$74.5M	0.29%	82
2018 Q1	$160M	Buy	2,532,500 +2,152,500	+566%	+$138M	0.67%	12
2017 Q4	$23.3M	Sell	380,000 -170,000	-31%	-$10.6M	0.07%	356
2017 Q3	$35.1M	Sell	550,000 -900,000	-62%	-$52.6M	0.14%	204
2017 Q2	$80.8M	Sell	1,450,000 -75,000	-5%	-$4.08M	0.33%	59
2017 Q1	$82.9M	Buy	1,525,000 +1,109,900	+267%	+$60.9M	0.39%	51
2016 Q4	$24.3M	Buy	415,100 +286,808	+224%	+$15.7M	0.13%	223
2016 Q3	$52K	Buy	128,292 +28,292	+28%	+$1.82M	﹤0.01%	946
2016 Q2	$7.36M	Sell	100,000 -50,000	-33%	-$3.53M	0.05%	427
2016 Q1	$9.58M	Buy	+150,000	New	+$9.46M	0.06%	413
2015 Q4	–	Sell	-200,000	Closed	-$11.8M	–	1240
2015 Q3	$11.8M	Buy	+200,000	New	+$12.7M	0.09%	303
2015 Q1	–	Sell	-69,300	Closed	-$4.09M	–	946
2014 Q4	$4.09M	Buy	+69,300	New	+$3.91M	0.04%	469
2014 Q2	–	Sell	-200,000	Closed	-$10.4M	–	641
2014 Q1	$10.4M	Buy	+200,000	New	+$10.6M	0.12%	219

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's BMY Position: Q1 2026 in Review

Balyasny Asset Management reduced its Bristol-Myers Squibb (BMY) stake by 91% in Q1 2026, selling an estimated $71.3M and leaving 118,697 shares worth $7.2M. The position accounts for 0.01% of the portfolio, ranked #1187.

Balyasny Asset Management first reported a position in BMY in Q1 2015 and has held it in 39 quarters since. The position peaked at $100M in Q4 2016. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Balyasny Asset Management held 118,697 shares of Bristol-Myers Squibb worth $7.2M as of Q1 2026.
Balyasny Asset Management sold 1,222,647 Bristol-Myers Squibb shares in Q1 2026, an estimated $71.3M.
Bristol-Myers Squibb made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1187 holding.
Balyasny Asset Management first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 39 quarters since.
Balyasny Asset Management's Bristol-Myers Squibb position peaked at $100M in Q4 2016.
2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.